Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients

Article English OPEN
Kerstjens, Huib A.; Bjermer, Leif; Eriksson, Leif; Dahlström, Kerstin; Vestbo, Jørgen;
(2010)
  • Publisher: Elsevier BV
  • Journal: Respiratory Medicine,volume 104,issue 9,pages1,297-1,303 (issn: 0954-6111)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1016/j.rmed.2010.04.010
  • Subject: CHEMOKINE RECEPTOR ANTAGONISTS | AZD4818 | BX471 | Pulmonary and Respiratory Medicine | Chemokine receptor antagonist | DISEASES | CP-481,715 | MICE | UMCG Approved | COPD | Disease modification

Objective: This study evaluated the tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in patients with COPD. Methods: This double-blind, placebo-controlled study (NCT00629239) randomised patients with moderate to severe COPD to AZD4818 300 mu g or placebo... View more
Share - Bookmark